Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;30(3):539-547.
doi: 10.3201/eid3003.231194.

Estimates of Incidence and Predictors of Fatiguing Illness after SARS-CoV-2 Infection

Quan M Vu, Annette L Fitzpatrick, Jennifer R Cope, Jeanne Bertolli, Nona Sotoodehnia, T Eoin West, Nikki Gentile, Elizabeth R Unger

Estimates of Incidence and Predictors of Fatiguing Illness after SARS-CoV-2 Infection

Quan M Vu et al. Emerg Infect Dis. 2024 Mar.

Abstract

This study aimed to estimate the incidence rates of post-COVID-19 fatigue and chronic fatigue and to quantify the additional incident fatigue caused by COVID-19. We analyzed electronic health records data of 4,589 patients with confirmed COVID-19 during February 2020-February 2021 who were followed for a median of 11.4 (interquartile range 7.8-15.5) months and compared them to data from 9,022 propensity score-matched non-COVID-19 controls. Among COVID-19 patients (15% hospitalized for acute COVID-19), the incidence rate of fatigue was 10.2/100 person-years and the rate of chronic fatigue was 1.8/100 person-years. Compared with non-COVID-19 controls, the hazard ratios were 1.68 (95% CI 1.48-1.92) for fatigue and 4.32 (95% CI 2.90-6.43) for chronic fatigue. The observed association between COVID-19 and the significant increase in the incidence of fatigue and chronic fatigue reinforces the need for public health actions to prevent SARS-CoV-2 infections.

Keywords: COVID-19; ME/CFS; PASC; PCC; SARS-CoV-2; coronavirus disease 2019; fatigue; incidence; myalgic encephalomyelitis/chronic fatigue syndrome; post COVID-19 conditions; post-acute sequelae of SARS-CoV-2 infection; respiratory infections; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Data flow for COVID-19 cases in study of incidence and predictors of fatiguing illness after SARS-CoV-2 infection, Washington, USA, February 2020–February 2021.
Figure 2
Figure 2
Cumulative incidence of fatigue (A) and chronic fatigue (B) among 4,589 COVID-19 cases and 9,022 non–COVID-19 controls in study of fatiguing illness after SARS-CoV-2 infection, Washington, USA, February 2020–February 2021. Shading around data lines indicates 95% CIs.
Figure 3
Figure 3
Clinical outcomes among COVID-19 patients with and without incident fatigue after SARS-CoV-2 infection in study of fatiguing illness after SARS-CoV-2 infection, Washington, USA, February 2020–February 2021.
See this image and copyright information in PMC

References

    1. Centers for Disease Control and Prevention. Long COVID—household pulse survey [cited 2023 Feb 6]. https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm
    1. Carfì A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603–5. 10.1001/jama.2020.12603 - DOI - PMC - PubMed
    1. O’Mahoney LL, Routen A, Gillies C, Ekezie W, Welford A, Zhang A, et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis. EClinicalMedicine. 2022;55:101762. 10.1016/j.eclinm.2022.101762 - DOI - PMC - PubMed
    1. Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, et al.; RECOVER Consortium. RECOVER Consortium. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA. 2023;329:1934–46. 10.1001/jama.2023.8823 - DOI - PMC - PubMed
    1. Bateman L, Bested AC, Bonilla HF, Chheda BV, Chu L, Curtin JM, et al. Myalgic Encephalomyelitis/chronic fatigue syndrome: essentials of diagnosis and management. Mayo Clin Proc. 2021;96:2861–78. 10.1016/j.mayocp.2021.07.004 - DOI - PubMed